

UK NEQAS FOR H SCHEME 3 - HLA ANTIBODY IDENTIFICATION

CLASS I & II IgM HLA ANTIBODY SPECIFICITY ANALYSIS OF 306-310/2017

DESPATCHED ON 13TH JUNE 2017

| Lab no. | 306/2017 IgM antibodies detected | | | 307/2017 IgM antibodies detected | | | 308/2017 IgM antibodies detected | | | 309/2017 IgM antibodies detected | | | 310/2017 IgM antibodies detected | | |
|------------|-------------------------------------|------------------------------------|--------|-------------------------------------|--------------------------|--------|-------------------------------------|---|--------|-------------------------------------|--|------------|-------------------------------------|---|--------|
| | Class I | Class II | Tech. | Class I | Class II | Tech. | Class I | Class II | Tech. | Class I | Class II | Tech. | Class I | Class II | Tech. |
| 42 162 | N | N DQA0505 DQA0601 DQA0503 | C L | N | N A32 A74 Cw5 Cw15 | C L | N | N A3303 DP14 A6801 DP19 B39 Cw2 Cw6 Cw12 Cw15 | C L | P | P A30 A31 DQA0302 A33 A34 DQA0503 A6602 DQ0505 A68 B13 DQA0601 Cw7 Cw4 Cw6 Cw17 | C L | N | N A6602 B7 B37 B4402 B46 B55 B82 Cw1 Cw2 Cw6 Cw7 Cw12 Cw16 Cw17 Cw14 | C L |
| 206 268 | | | | Cw5 | | LCT | | | | A30 A31 anti A30 anti A31 | | LCT CDC | | | |

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

UK NEQAS FOR H SCHEME 3 - HLA ANTIBODY IDENTIFICATION

CDC % PRA OF 306-310/2017

DESPATCHED ON 13TH JUNE 2017

| Lab no. | T-cell CDC % PRA | B-cell CDC % PRA | PBL CDC % PRA | 306/2017 | | | CDC Specificities Detected | 307/2017 | | | CDC Specificities Detected | 308/2017 | | | CDC Specificities Detected | 309/2017 | | | CDC Specificities Detected | 310/2017 | | | CDC Specificities Detected |
|---------|------------------|------------------|---------------|----------|--------|-----|----------------------------|----------|--------|-----|----------------------------|----------|--------|-----|----------------------------|-------------------|--------|-----|----------------------------|----------|--------|-----|----------------------------|
| | | | | T-cell | B-cell | PBL | | T-cell | B-cell | PBL | | T-cell | B-cell | PBL | | T-cell | B-cell | PBL | | T-cell | B-cell | PBL | |
| 42 | | 26 | 40 | NT | NT | 0 | NEG | NT | NT | 0 | NEG | NT | NT | 0 | NEG | NT | NT | 5 | IgM undefined | NT | NT | 0 | NEG |
| 116 | | | | | 15 | | | | 8 | | | 0 | | | | | 0 | | A30 | | 0 | | A29 |
| 136 | | | 48 | | | 2 | B27 | | | 8 | A31 | | 2 | | | | 18 | | A30 | | 2 | | |
| 206 | | | | | | | | | | 15 | Cw5 | | | | | | 25 | | A30 A31 | | | | |
| 209 | | | | 0 | NT | NT | | 0 | NT | NT | | 0 | NT | NT | | 7 (before DTT) | NT | NT | A30 A31 | 0 | NT | NT | |
| 268 | | | | 0 | NT | NT | | 0 | NT | NT | | 0 | NT | NT | | 20 | NT | NT | A30 A31 | 10 | NT | NT | |

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

UK NEQAS FOR H SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 306/2017

DESPATCHED ON 13TH JUNE 2017

Complement fixing antibodies detected using solid phase assays - NOT ASSESSED

B81

Consensus Not Assessed
% reported 25.0%

| Lab no. | spec |
|---------|------|
| 114 | |
| 120 | B81 |
| 273 | |
| 284 | |

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

| | |
|--------|---|
| Number | 1 |
| Total | 4 |

UK NEQAS FOR H SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 307/2017

DESPATCHED ON 13TH JUNE 2017

Complement fixing antibodies detected using solid phase assays - NOT ASSESSED

Cw5

Consensus Not Assessed
% reported 25.0%

| Lab no. | spec |
|---------|------|
| 114 | Cw5 |
| 120 | |
| 273 | |
| 284 | |

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

| | |
|--------|---|
| Number | 1 |
| Total | 4 |

UK NEQAS FOR H SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 308/2017

DESPATCHED ON 13TH JUNE 2017

Complement fixing antibodies detected using solid phase assays - NOT ASSESSED

Consensus
% reported

Lab no.

114 No antibodies reported

120

273

284

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number

Total

UK NEQAS FOR H SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 309/2017

DESPATCHED ON 13TH JUNE 2017

Complement fixing antibodies detected using solid phase assays - NOT ASSESSED

| | A30 | A31 |
|------------|--------------|--------------|
| Consensus | Not Assessed | Not Assessed |
| % reported | 25.0% | 25.0% |
| Lab no. | spec | spec |
| 114 | | |
| 120 | | |
| 273 | A30 | A31 |
| 284 | | |

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

| | | |
|--------|---|---|
| Number | 1 | 1 |
| Total | 4 | 4 |

UK NEQAS FOR H SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 310/2017

DESPATCHED ON 13TH JUNE 2017

Complement fixing antibodies detected using solid phase assays - NOT ASSESSED

Consensus
% reported

Lab no.

114 No antibodies reported

120

273

284

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number

Total

UK NEQAS FOR H SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 306/2017

DESPATCHED ON 13TH JUNE 2017

| Unacceptable antigen listing - NOT ASSESSED | | | | | | | | | | | | | | | | | | | | | | | | |
|--|-----------------------|-----------------|-----------------|-------------------|------------------------|------------------------|-----------------------|-----------------------|------------------------|-----------------------|-----------------|------------------------|-----------------------|------------------------|-----------------------|------------------------|-------------------------|------------------------|--------------------|-------------------|-------------------|-------------------|-------------------|------|
| Consensu. % reporte | A3 Not Assessed 35.7% | A23 Absent 3.6% | A24 Absent 3.6% | A2403 Absent 3.6% | A30 Not Assessed 32.1% | A31 Not Assessed 67.9% | B7 Not Assessed 21.4% | B8 Not Assessed 39.3% | B13 Not Assessed 60.7% | B81 Not Assessed 7.1% | Cw4 Absent 3.6% | DR17 Not Assessed 7.1% | DR4 Not Assessed 7.1% | DR7 Not Assessed 46.4% | DR9 Not Assessed 7.1% | DR10 Not Assessed 7.1% | DR53 Not Assessed 32.1% | DQ5 Not Assessed 67.9% | DQ2 Present 100.0% | DQ7 Present 85.7% | DQ8 Present 82.1% | DQ9 Present 82.1% | DQ4 Present 82.1% | |
| Lab no. | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec |
| 11 | | | | | | A31 | | | B13 | | | | | DR7 | | | DR53 | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 14 | | | | | | A31 | | | | | | | | | | | | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 15 | | | | | | A31 | | B8 | | | | | | | | | | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 24 | A3 | | | | A30 | A31 | B7 | B8 | B13 | B81 | Cw4 | | | DR7 | | DR10 | DR53 | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 25 | A3 | | | | A30 | A31 | | B8 | B13 | | | | | DR7 | | | DR53 | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 34 | | | | | A30 | A31 | | B8 | B13 | | | | | DR7 | | | DR53 | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 38 | A3 | | | | A30 | A31 | B7 | B8 | B13 | | | | | DR7 | | | DR53 | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 39 | | | | | | | | | | | | | | | | | | | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 41 | A3 | | | | | A31 | | | B13 | | | | | | | | | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 48 | A3 | | | | A30 | A31 | B7 | B8 | B13 | B81 | | | | | | | | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 58 | A3 | | | | A30 | A31 | | B8 | B13 | | | | | DR7 | | | DR53 | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 62 | | | | | | A31 | | B8 | B13 | | | | | | | | | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 112 | | | | | | | | | | | | | | | | | | | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 114 | A3 | | | | A30 | A31 | | | B13 | | | | | DR7 | | | | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 117 | | | | | | | | | | | | | | | | | | | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 119 | A3 | | | | | A31 | B7 | | B13 | | | | | DR7 | | | | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 120 | | | | | | | | | B13 | | | | | | | | | | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 133 | | | | | | | | | | | | | | | | | | | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 142 | | | | | | | | | | | | | | | | | | | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 145 | | | | | | A31 | | | B13 | | | | | | | | | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 162 | A3 | | | | A30 | A31 | B7 | | B13 | | | | | DR7 | | | | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 185 | | | | | | | | | | | | | | | | | | | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 195 | | | | | | A31 | | | B13 | | | | | | | | | | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 204 | | | | | | A31 | | B8 | | | | DR17 | DR4 | DR7 | DR9 | DR10 | DR53 | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 206 | | | | | | A31 | | | B13 | | | | | | | | | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 209 | | | | | | A31 | | B8 | B13 | | | | DR4 | DR7 | DR9 | | | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| 218 | | A23 | A24 | A2403 | | | | B8 | | | | DR17 | | DR7 | | | DR53 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | | |
| 284 | A3 | | | | A30 | A31 | B7 | B8 | B13 | | | | | DR7 | | | DR53 | DQ5 | DQ2 | DQ7 | DQ8 | DQ9 | DQ4 | |
| Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other | | | | | | | | | | | | | | | | | | | | | | | | |
| Number | 10 | 1 | 1 | 1 | 9 | 19 | 6 | 11 | 17 | 2 | 1 | 2 | 2 | 13 | 2 | 2 | 9 | 19 | 28 | 24 | 23 | 23 | 23 | 23 |
| Total | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |

UK NEQAS FOR H SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 307/2017

DESPATCHED ON 13TH JUNE 2017

Unacceptable antigen listing - NOT ASSESSED

| Consensu. % reporte | A2 Absent 3.6% | A203 Absent 3.6% | A24 Absent 3.6% | A2403 Absent 3.6% | A25 Absent 3.6% | A66 Absent 3.6% | B73 Absent 3.6% | Cw2 Present 82.1% | Cw9 Not Assesse 7.1% | Cw10 Not Assesse 21.4% | Cw4 Present 82.1% | Cw5 Present 82.1% | Cw6 Present 85.7% | Cw8 Present 75.0% | Cw12 Not Assesse 17.9% | Cw15 Present 85.7% | Cw16 Not Assesse 10.7% | Cw17 Present 85.7% | Cw18 Present 82.1% | DR1 Not Assesse 67.9% | DR17 Absent 3.6% | DR4 Present 96.4% | DR11 Absent 3.6% | DR14 Not Assesse 32.1% | DR10 Not Assesse 17.9% | DQ7 Present 92.9% | DQ8 Present 85.7% | DQ9 Present 82.1% | DQ4 Absent 3.6% | |
|---------------------|----------------------|------------------------|-----------------------|-------------------------|-----------------------|-----------------------|-----------------------|-------------------------|----------------------------|------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|------------------------------|--------------------------|------------------------------|--------------------------|--------------------------|-----------------------------|------------------------|-------------------------|------------------------|------------------------------|------------------------------|-------------------------|-------------------------|-------------------------|-----------------------|------|
| Lab no. | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec |
| 11 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 14 | | | | | | | | Cw2 | | | | | | | | | | | | | | | | | | | | | | |
| 15 | | | | | | | | Cw2 | | | | | | | | | | | | | | | | | | | | | | |
| 24 | | | | | | | | Cw2 | | Cw10 | | | | | | | | | | | | | | | | | | | | |
| 25 | | | | | | | | Cw2 | | | | | | | | | | | | | | | | | | | | | | |
| 34 | | | | | | | | Cw2 | | Cw10 | | | | | | | | | | | | | | | | | | | | |
| 38 | | | | | | | | Cw2 | | Cw9 | | | | | | | | | | | | | | | | | | | | |
| 39 | | | | | | | | Cw2 | | Cw10 | | | | | | | | | | | | | | | | | | | | |
| 41 | | | | | | | | Cw2 | | | | | | | | | | | | | | | | | | | | | | |
| 48 | | | | | | | | Cw2 | | | | | | | | | | | | | | | | | | | | | | |
| 58 | | | | | | | | Cw2 | | Cw10 | | | | | | | | | | | | | | | | | | | | |
| 62 | | | | | | | | Cw2 | | | | | | | | | | | | | | | | | | | | | | |
| 112 | | | | | | | | Cw2 | | | | | | | | | | | | | | | | | | | | | | |
| 114 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 117 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 119 | | | | | | | | Cw2 | | | | | | | | | | | | | | | | | | | | | | |
| 120 | | | | | | | | Cw2 | | | | | | | | | | | | | | | | | | | | | | |
| 133 | | | | | | | | Cw2 | | | | | | | | | | | | | | | | | | | | | | |
| 145 | | | | | | | | Cw2 | | | | | | | | | | | | | | | | | | | | | | |
| 142 | | | | | | | | Cw2 | | | | | | | | | | | | | | | | | | | | | | |
| 162 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 185 | | | | | | | | Cw2 | | | | | | | | | | | | | | | | | | | | | | |
| 195 | | | | | | | | Cw2 | | | | | | | | | | | | | | | | | | | | | | |
| 204 | | | | | | | | Cw2 | | | | | | | | | | | | | | | | | | | | | | |
| 206 | | | | | | | | Cw2 | | | | | | | | | | | | | | | | | | | | | | |
| 209 | | | | | | | | Cw2 | | | | | | | | | | | | | | | | | | | | | | |
| 218 | A2 | A203 | A24 | A2403 | A25 | A66 | | | | | | | | | | | | | | | | | | | | | | | | |
| 284 | | | | | | | | Cw2 | | Cw10 | | | | | | | | | | | | | | | | | | | | |

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--------|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|
| Number | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 23 | 2 | 6 | 23 | 23 | 24 | 21 | 5 | 24 | 3 | 24 | 23 | 19 | 1 | 27 | 1 | 9 | 5 | 26 | 24 | 23 | 1 |
| Total | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |

UK NEQAS FOR H SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 308/2017

DESPATCHED ON 13TH JUNE 2017

| Unacceptable antigen listing - NOT ASSESSED | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|-----------------------|-----------------------|-------------------------|--------------------------------|-------------------------|------------------------------|------------------------------|-----------------------|-------------------------|-----------------------|------------------------------|------------------------------|------------------------------|-------------------------------|-------------------------------|-------------------------------|-----------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|--------------------------|--------------------------|------------------------------|------------------------|
| Consensus % reported | A30 Absent 3.6% | A43 Absent 3.6% | B51 Present 78.6% | B5102 Not Assessec 28.6% | B5103 Absent 3.6% | B75 Not Assessec 53.6% | B77 Not Assessec 39.3% | B38 Absent 3.6% | B35 Present 75.0% | B37 Absent 3.6% | B53 Not Assessec 71.4% | B71 Not Assessec 50.0% | B78 Not Assessec 60.7% | DR16 Not Assessec 17.9% | DR17 Not Assessec 32.1% | DR18 Not Assessec 21.4% | DR4 Not Assessec 7.1% | DR11 Not Assessec 60.7% | DR12 Not Assessec 17.9% | DR13 Not Assessec 64.3% | DR14 Not Assessec 64.3% | DR1403 Absent 3.6% | DR1404 Absent 3.6% | DR8 Not Assessec 71.4% | DR52 Absent 3.6% |
| Lab no. | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec | spec |
| 11 | | | B51 | B5102 | | B75 | B77 | | B35 | | B53 | B71 | | | | | | DR11 | | DR13 | DR14 | | | DR8 | |
| 14 | | | B51 | B5102 | | | | | B35 | | B53 | | | | | | | | | DR13 | DR14 | | | DR8 | |
| 15 | | | B51 | | | | | | B35 | | | | | | | | | | | | | | | DR8 | |
| 24 | | | B51 | | | B75 | B77 | | B35 | | B53 | B71 | | | DR17 | | | DR11 | | DR13 | DR14 | | | DR8 | |
| 25 | | | B51 | | | B75 | | | B35 | | B53 | B71 | B78 | | DR17 | DR18 | | DR11 | | DR13 | DR14 | | | DR8 | |
| 34 | A30 | | B51 | B5102 | | B75 | B77 | | B35 | B37 | B53 | B71 | B78 | DR16 | | DR18 | | DR11 | | DR13 | DR14 | | | DR8 | |
| 38 | | | B51 | | | B75 | B77 | B38 | B35 | | B53 | B71 | B78 | | DR17 | DR18 | | DR11 | DR12 | DR13 | DR14 | | | DR8 | |
| 39 | | | | | | | | | | | | | | | | | | | | | | | | DR52 | |
| 41 | | | B51 | | | B75 | | | B35 | | B53 | B71 | B78 | | | | | DR11 | | DR13 | DR14 | | | DR8 | |
| 48 | | | B51 | B5102 | | B75 | B77 | | B35 | | B53 | B71 | B78 | | DR17 | DR18 | | DR11 | DR12 | DR13 | DR14 | | | DR8 | |
| 58 | | | B51 | | | B75 | B77 | | B35 | | B53 | B71 | B78 | DR16 | DR17 | | | DR11 | | DR13 | DR14 | | | DR8 | |
| 62 | | | | | | | | | B35 | | B53 | | B78 | | | | | | | | | | | DR8 | |
| 112 | | | B51 | B5102 | | | | | | | B53 | B71 | | | | | | | | | | | | DR8 | |
| 114 | | | B51 | B5102 | B5103 | B75 | B77 | | B35 | | B53 | B71 | B78 | DR16 | DR17 | DR18 | DR4 | DR11 | | DR13 | DR14 | | | DR8 | |
| 117 | | | | | | | | | | | | | | | | | | | | | | | | DR8 | |
| 119 | | | B51 | B5102 | | B75 | | | B35 | | B53 | | B78 | | DR17 | | | DR11 | | DR13 | DR14 | | | DR8 | |
| 120 | | | B51 | | | | | | B35 | | | | | | | | | | | | | | | DR8 | |
| 133 | | | | | | | | | | | | | | | | | | | | | | | | DR8 | |
| 142 | | | | | | | | | | | | | | | | | | | | | | | | DR8 | |
| 145 | | | B51 | | | | | | B35 | | B53 | | B78 | | | | | DR11 | DR12 | DR13 | DR14 | | | DR8 | |
| 162 | | | B51 | | | B75 | B77 | | | | B53 | B71 | B78 | | | | | DR11 | | DR13 | DR14 | | | DR8 | |
| 185 | | | | | | | | | | | | | | | | | | | | | | | | DR8 | |
| 195 | | | B51 | B5102 | | | | | B35 | | B53 | | | | | | | DR11 | | DR13 | DR14 | | | DR8 | |
| 204 | | | B51 | | | B75 | B77 | | B35 | | B53 | B71 | B78 | DR16 | DR17 | DR18 | | DR11 | DR12 | DR13 | DR14 | | | DR8 | |
| 206 | | | B51 | | | | | | B35 | | B53 | | B78 | | | | | | | | | | | DR8 | |
| 209 | | | B51 | | | B75 | | | B35 | | B53 | B71 | B78 | | | | | DR11 | | DR13 | DR14 | | | DR8 | |
| 218 | | A43 | B51 | | | B75 | B77 | | B35 | | B53 | B71 | B78 | | DR17 | DR18 | | DR11 | DR12 | DR13 | DR14 | DR1403 | DR1404 | DR8 | |
| 284 | | | B51 | | | B75 | B77 | | B35 | | B53 | B71 | B78 | DR16 | | | DR4 | DR11 | | DR13 | DR14 | | | DR8 | |

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

| | | | | | | | | | | | | | | | | | | | | | | | | | |
|--------|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|
| Number | 1 | 1 | 22 | 8 | 1 | 15 | 11 | 1 | 21 | 1 | 20 | 14 | 17 | 5 | 9 | 6 | 2 | 17 | 5 | 18 | 18 | 1 | 1 | 20 | 1 |
| Total | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |

UK NEQAS FOR H SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 309/2017

DESPATCHED ON 13TH JUNE 2017

Unacceptable antigen listing - NOT ASSESSED

| | A23 | A24 | A2403 | A30 | A31 | B48 | DR53 |
|------------|--------|--------|--------|--------------|--------------|--------------|--------|
| Consensus | Absent | Absent | Absent | Not Assessed | Not Assessed | Not Assessed | Absent |
| % reported | 3.6% | 3.6% | 3.6% | 7.1% | 7.1% | 7.1% | 3.6% |
| Lab no. | spec | spec | spec | spec | spec | spec | spec |
| 9 | | | | | | | |
| 14 | | | | | | | |
| 15 | | | | | | B48 | |
| 24 | | | | | | | |
| 25 | | | | | | | |
| 34 | | | | | | | |
| 38 | | | | A30 | A31 | | DR53 |
| 39 | | | | | | | |
| 41 | | | | | | | |
| 48 | | | | | | | |
| 58 | | | | | | | |
| 62 | | | | | | | |
| 112 | | | | | | | |
| 114 | | | | | | | |
| 117 | | | | | | | |
| 119 | | | | | | | |
| 120 | | | | | | | |
| 133 | | | | | | | |
| 142 | | | | | | | |
| 145 | | | | | | | |
| 162 | | | | | | | |
| 185 | | | | | | | |
| 195 | | | | | | | |
| 204 | | | | | | | |
| 206 | | | | | | | |
| 209 | | | | | | | |
| 218 | A23 | A24 | A2403 | A30 | A31 | | |
| 284 | | | | | | B48 | |

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

| | | | | | | | |
|--------|----|----|----|----|----|----|----|
| Number | 1 | 1 | 1 | 2 | 2 | 2 | 1 |
| Total | 28 | 28 | 28 | 28 | 28 | 28 | 28 |

UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351.

© Confidential report; no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H SCHEME 3 - HLA ANTIBODY IDENTIFICATION

SOLID PHASE ASSAY COMPLEMENT FIXING ANTIBODIES 310/2017

DESPATCHED ON 13TH JUNE 2017

Unacceptable antigen listing - NOT ASSESSED

| | A24 | A2403 | A66 | B46 | DR51 | DQ5 | DQ6 |
|------------|--------|--------|--------|--------|--------|--------|--------|
| Consensus | Absent | Absent | Absent | Absent | Absent | Absent | Absent |
| % reported | 3.6% | 3.6% | 3.6% | 3.6% | 3.6% | 3.6% | 3.6% |
| Lab no. | spec | spec | spec | spec | spec | spec | spec |
| 9 | | | | | | | |
| 14 | | | | B46 | | | |
| 15 | | | | | | | |
| 24 | | | | | | | |
| 25 | | | | | | | |
| 34 | | | | | DR51 | | |
| 38 | | | | | | | |
| 39 | | | | | | | |
| 41 | | | | | | | |
| 48 | | | | | | | |
| 58 | | | | | | | |
| 62 | | | | | | | |
| 112 | | | | | | | |
| 114 | | | | | | | |
| 117 | | | | | | | |
| 119 | | | | | | | |
| 120 | | | | | | | |
| 133 | | | | | | | |
| 142 | | | | | | | |
| 145 | | | | | | | |
| 162 | | | | | | | |
| 185 | | | | | | | |
| 195 | | | | | | | |
| 204 | | | | | | | |
| 206 | | | | | | | |
| 209 | | | | | | | |
| 218 | A24 | A2403 | A66 | | | DQ5 | DQ6 |
| 284 | | | | | | | |

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

| | | | | | | | |
|--------|----|----|----|----|----|----|----|
| Number | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 28 | 28 | 28 | 28 | 28 | 28 | 28 |

UK NEQAS for H&I is operated by Velindre NHS Trust, a UKAS proficiency testing provider No 8351.

© Confidential report; no data may be published without permission from UK NEQAS for H&I

NEQ-121
Issue 3
P 12 of 12
Effective Date 13/03/17